M. Janssens MD, K. Saevels MD, V. Vergote MD, J. Lemmens MD, S. Bailly MD, A. Janssens MD, PhD, S. Snauwaert MD, PhD, M. André MD, PhD
SUMMARY
Besides disease-directed therapy, patients with lymphoma are in need of a wide range of supportive measures. In the second part of this guideline, the prevention and treatment of tumour lysis syndrome, cardiac support and physiotherapy are discussed.
M. Janssens MD, K. Saevels MD, V. Vergote MD, J. Lemmens MD, S. Bailly MD, A. Janssens MD, PhD, S. Snauwaert MD, PhD, M. André MD, PhD
SUMMARY
Besides disease-directed therapy, patients with lymphoma are in need of a wide range of supportive measures. In the first part of this guideline the use of anti-emetic therapy, the use of granulocyte colony stimulating factor (G-CSF) and antibiotic prophylaxis for pneumocystis jirovecii are discussed. In part 2 of this guideline we will discuss cardiac support, prevention and treatment of tumour lysis syndrome and the role of physiotherapy.
A. Wolfromm MD, S. Bailly MD, E. Van den Neste MD, PhD, M. André MD, PhD, K. Saevels MD, H. Antoine-Poirel MD, PhD, T. Tousseyn MD, PhD, V. Van Hende MD, S. Snauwaert MD, PhD, A. Janssens MD, PhD, C. Jacquy MD, C. Bonnet MD, PhD
SUMMARY
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive diseases associated with poor outcomes. Recent progress in understanding of the biology and pathogenesis based on molecular profiling and next-generation sequencing has led to the introduction of new provisional entities in the World Health Organization (WHO) classification system of 2017 and to the emergence of new drugs.1 Previous Belgian guidelines were published in 2013.2 This review will discuss the diagnosis, work-up and treatment of PTCL including these advances as well as the limitation of the availability of drugs according to the Belgian reimbursement rules.
G. Swennen MD, A. Janssens MD, PhD, V. Vergote MD, S. Bailly MD, C. Bonnet MD, PhD, E. Van den Neste MD, PhD, M. Maerevoet MD, S. Snauwaert MD, PhD, K. Saevels MD, C. Jacquy MD
SUMMARY
Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma. Prognosis of diffuse large B-cell lymphoma has improved dramatically since the introduction of rituximab and about two thirds of patients can be cured with immunochemotherapy. In the last twenty years, it became clear that diffuse large B-cell lymphoma is a very heterogeneous disease and based on the genetic mutation landscapes numerous efforts have been made to develop novel treatment strategies to improve the prognosis of diffuse large B-cell lymphoma further. This article provides an update of diagnosis, current treatment guidelines and novel treatment strategies for newly diagnosed patients with diffuse large B-cell lymphoma in Belgium. It will also focus on treatment of elderly patients and high-grade B-cell lymphoma.
BJH - volume 11, issue Abstract Book BHS, february 2020
F. Andreozzi , I. Dufour , A. Sogorb , S. Chabert , G. Verstraete , J. Raedemaeker , L. Bamps , S. Bailly MD, F. Jamar , F. Lecouvet , A. Camboni MD, PhD, J-P. Defour PhD, dr. A-C. Pouleur , J. Morelle MD, PhD, M-C. Vekemans MD, PhD
BJH - volume 11, issue Abstract Book BHS, february 2020
I. Dufour , G. Verstraete , J. Raedemaeker , F. Andreozzi , L. Bamps , S. Chabert , A. Sogorb , S. Bailly MD, E. Van den Neste MD, PhD, X. Theunssens , F. Tamirou , D. Tennstedt , A. Camboni MD, PhD, M-C. Vekemans MD, PhD
BJH - volume 11, issue Abstract Book BHS, february 2020
J. Raedemaeker , F. Andreozzi , I. Dufour , L. Bamps , G. Verstraete , S. Chabert , S. Bailly MD, D. Maisin , J-P. Defour PhD, A. Camboni MD, PhD, dr. A-C. Pouleur , B. Gerber , F. Lecouvet , M-C. Vekemans MD, PhD
